For example, EGFR-mutated NSCLC frequently responds better to treatment with EGFR-TKIs, such as gefitinib and erlotinib, which have significantly improved the outlook for lung cancer patients and given them new hope, but their efficacy has been hampered by the emergence of acquired drug resistance (109). This evidence concerns the gene EGFR and lung carcinoma.